JonesResearch analyst Justin Walsh reiterates a Buy rating on Radiopharm (RADX) and announced a $30 price target on the U.S. shares. The firm remains “intrigued” by the potential of the company’s “diverse” radiopharmaceutical pipeline and believes the market is “dramatically undervaluing the opportunity.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX: